BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22392197)

  • 1. Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.
    Ghosn M; Saroufim A; Kattan J; Chahine G; Nasr F; Farhat F
    Med Oncol; 2012 Dec; 29(4):2831-7. PubMed ID: 22392197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
    Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
    Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
    Hecht JR; Lonardi S; Bendell J; Sim HW; Macarulla T; Lopez CD; Van Cutsem E; Muñoz Martin AJ; Park JO; Greil R; Wang H; Hozak RR; Gueorguieva I; Lin Y; Rao S; Ryoo BY
    J Clin Oncol; 2021 Apr; 39(10):1108-1118. PubMed ID: 33555926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
    Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
    J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
    Neuzillet C; Hentic O; Rousseau B; Rebours V; Bengrine-Lefèvre L; Bonnetain F; Lévy P; Raymond E; Ruszniewski P; Louvet C; Hammel P
    World J Gastroenterol; 2012 Sep; 18(33):4533-41. PubMed ID: 22969226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
    Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
    Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
    Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
    Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
    Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E;
    Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
    Hammel P; Fabienne P; Mineur L; Metges JP; Andre T; De La Fouchardiere C; Louvet C; El Hajbi F; Faroux R; Guimbaud R; Tougeron D; Bouche O; Lecomte T; Rebischung C; Tournigand C; Cros J; Kay R; Hamm A; Gupta A; Bachet JB; El Hariry I
    Eur J Cancer; 2020 Jan; 124():91-101. PubMed ID: 31760314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
    J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
    Safran H; Charpentier KP; Perez K; Mantripragada K; Miner T; DiPetrillo T; Kuritzky B; Apor E; Bishop K; Luppe D; Mitchell K; Rosati K
    Am J Clin Oncol; 2016 Dec; 39(6):619-622. PubMed ID: 26523444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.